Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to -$8.7 million.

  • vTv Therapeutics' Net Income towards Common Stockholders fell 8185.24% to -$8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.5 million, marking a year-over-year decrease of 2820.93%. This contributed to the annual value of -$18.5 million for FY2024, which is 882.96% up from last year.
  • Latest data reveals that vTv Therapeutics reported Net Income towards Common Stockholders of -$8.7 million as of Q3 2025, which was down 8185.24% from -$6.0 million recorded in Q2 2025.
  • Over the past 5 years, vTv Therapeutics' Net Income towards Common Stockholders peaked at -$608000.0 during Q2 2021, and registered a low of -$8.7 million during Q3 2025.
  • Over the past 5 years, vTv Therapeutics' median Net Income towards Common Stockholders value was -$4.9 million (recorded in 2024), while the average stood at -$4.9 million.
  • The largest annual percentage gain for vTv Therapeutics' Net Income towards Common Stockholders in the last 5 years was 8781.81% (2021), contrasted with its biggest fall of 53876.79% (2021).
  • Over the past 5 years, vTv Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$7.1 million in 2021, then soared by 32.7% to -$4.7 million in 2022, then rose by 26.7% to -$3.5 million in 2023, then decreased by 4.49% to -$3.6 million in 2024, then plummeted by 139.35% to -$8.7 million in 2025.
  • Its last three reported values are -$8.7 million in Q3 2025, -$6.0 million for Q2 2025, and -$5.1 million during Q1 2025.